2 weeks Ago By ABMN Staff
Summit Investment Advisors Inc. lowered its stake in shares of Humana Inc. ( NYSE:HUM – Free Report ) by 3.
9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,173 shares of the insurance provider’s stock after selling 47 shares during the period.
Summit Investment Advisors Inc.’s holdings in Humana were worth $298,000 at the end of the most recent quarter. A number of other large investors also recently added to or reduced their stakes in the company.
Vanguard Group Inc. lifted its stake in Humana by 15.8% during the 4th quarter.
Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock worth $3,254,899,000 after acquiring an additional 1,751,857 shares in the last quarter. Norges Bank purchased a new position in shares of Humana in the fourth quarter valued at approximately $416,202,000.
Pzena Investment Management LLC increased its stake in Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after buying an additional 1,103,132 shares during the period.
Boston Partners lifted its holdings in Humana by 435.8% during the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after buying an additional 893,637 shares in the last quarter.
Finally, Invesco Ltd. boosted its position in Humana by 29.8% in the 4th quarter.
Invesco Ltd. now owns 2,397,808 shares of the insurance provider’s stock valued at $608,348,000 after buying an additional 550,692 shares during the period. 92.
38% of the stock is currently owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades Several analysts have recently issued reports on HUM shares. Morgan Stanley reduced their price objective on Humana from $301.
00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Truist Financial lifted their price objective on Humana from $290.
00 to $325.00 and gave the company a “hold” rating in a research note on Friday, April 11th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.
00 target price on shares of Humana in a report on Wednesday, February 12th. Robert W. Baird boosted their price target on shares of Humana from $270.
00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, April 15th. Finally, JPMorgan Chase & Co.
reduced their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th.
Seventeen investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Humana currently has an average rating of “Hold” and a consensus target price of $284.90.
Humana Price Performance Shares of HUM opened at $264.41 on Monday. The company has a debt-to-equity ratio of 0.
68, a quick ratio of 1.76 and a current ratio of 1.76.
Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.
46. The firm has a 50-day simple moving average of $265.90 and a 200-day simple moving average of $270.
22. The company has a market capitalization of $31.91 billion, a price-to-earnings ratio of 26.
57, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62.
Humana ( NYSE:HUM – Get Free Report ) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.
26) by $0.10. Humana had a return on equity of 11.
70% and a net margin of 1.02%. On average, equities research analysts anticipate that Humana Inc.
will post 16.47 earnings per share for the current year. Humana Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th.
Shareholders of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.
54 dividend on an annualized basis and a yield of 1.34%. Humana’s payout ratio is currently 35.
58%. Humana Profile ( Free Report ) Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell.
The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. Further Reading Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Humana Inc. ( NYSE:HUM – Free Report ). Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.
com's FREE daily email newsletter ..
